PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
Why now
Thesis: ST-920 acquisition advances PTC pipeline toward BLA submission
Catalyst to watch: BLA submission or FDA regulatory decision
Main risk: Clinical setbacks or regulatory rejection
Why it matters
Completing the ST-920 gene therapy acquisition advances PTC's pipeline toward a BLA submission, a potential catalyst.
Details
– Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time...
Sources
- prnewswire · 2026-09-21 20:30 UTC